UnknownPHASE1, PHASE2NCT04206943
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL
Studying T-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Acibadem University
- Principal Investigator
- Ercument Ovali, MDDirector
- Intervention
- Car-T Cell Therapy(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 3-65 years · All sexes
- Timeline
- 2019 – 2021
Study locations (1)
- Acıbadem Labcell Cellular Therapy Laboratories, Istanbul, Turkey (Türkiye)
Collaborators
Acıbadem Atunizade Hospital · The Scientific and Technological Research Council of Turkey · Acıbadem Labcell
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04206943 on ClinicalTrials.govOther trials for T-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05989204TmCD19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT05377827Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT04440436Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsBeijing Immunochina Medical Science & Technology Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT03434769AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaBenjamin Tomlinson
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02690545Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLUNC Lineberger Comprehensive Cancer Center